{
  "chapter": "Pulmonology-Bronchial Asthma And Copd",
  "questions": [
    {
      "q_no": 1,
      "question": "A 55-year-old male with a history of heavy smoking presents with a cough and sputum production for 4 months. Which statement is true regarding his condition?",
      "options": {
        "A": "Diagnosis requires symptoms for at least 2 consecutive months.",
        "B": "Smoking cessation is the only intervention that positively impacts COPD",
        "C": "Inhaled bronchodilators are the primary treatment for chronic bronchitis.",
        "D": "Hemoptysis is the initial symptom indicative of chronic bronchitis."
      },
      "correct_answer": "B",
      "explanation": "bronchitis and COPD, improving lung function and slowing the decline in FEV1. Reid index: used to quantify the severity of chronic bronchitis. It is calculated by taking the ratio of the thickness of mucous glands to the thickness of total respiratory structures. Reid Index=Total thickness of the bronchial wall/Thickness of the mucous gland layer I Normal Reid Index : Typically around 0.4 . Chronic Bronchitis : A Reid Index greater than 0.4. Chronic Bronchitis Cough and sputum production lasting for at least 3 months in each of 2 consecutive years. (Option A ruled out) One of the phenotypes associated with COPD, alongside emphysema. Large bronchi overtime become inflamed and scarred. Cigarette smoking (95% of COPD cases in the UK attributed to tobacco smoke). Initial symptoms include cough, sputum production, and \"smoker's cough\"; hemoptysis may occur during exacerbations. (Option D ruled out) Consider chronic asthma, tuberculosis, bronchiectasis, congestive heart failure. Chest X-ray, blood count, and alpha-1 antitrypsin assay to rule out other conditions. Reduce exposure to harmful particles and manage symptoms. Smoking cessation (only intervention that positively impacts COPD) (Option B) , inhaled bronchodilators (Option C ruled out) , glucocorticoids. Generally progressive; influenced by age (inversely related) and post-bronchodilator FEV1 (directly related). Weight loss, pulmonary hypertension; common causes of death include respiratory failure, cardiac disease, and lung cancer. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 574. 575, 576.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 2,
      "question": "A 68-year-old male patient with COPD presents with severe respiratory distress. Before initiating Non-Invasive Ventilation (NIV), which of the following conditions would be considered as absolute contraindication?",
      "options": {
        "A": "Severe hypoxemia with pH < 7.1",
        "B": "Lack of spontaneous breathing or gasping",
        "C": "Post upper gastrointestinal surgery",
        "D": "Massive retention of secretions despite bronchoscopy"
      },
      "correct_answer": "B",
      "explanation": "Correct answer: B) Lack of spontaneous breathing or gasping Explanation: This condition indicates the patient cannot initiate breaths independently, making NIV inappropriate and potentially leading to respiratory failure. Contraindications for Non-Invasive Ventilation (NIV): Categories : Contraindications are divided into absolute and relative categories. Absolute Contraindications: NIV should not be used under any circumstances: Lack of spontaneous breathing or gasping : Patients unable to initiate breaths independently. Anatomical or functional airway obstruction : Conditions obstructing airflow. Gastrointestinal bleeding or ileus : Conditions increasing aspiration risk. Relative Contraindications: NIV may be attempted with careful monitoring and readiness for intubation: Coma : Altered consciousness affecting NIV tolerance. Massive agitation : Severe restlessness impacting NIV effectiveness. Massive retention of secretions : Excessive secretions obstructing airflow, despite bronchoscopy. (Option D ruled out) Severe hypoxemia or acidosis (pH < 7.1) : Conditions of critical respiratory failure. (Option A ruled out) Hemodynamic instability : Conditions like cardiogenic shock affecting patient stability. Anatomical or subjective difficulty accessing the airway : Challenges in airway management. Status post upper gastrointestinal surgery : Risk assessment based on surgery type and timing. (Option C ruled out) Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 578 https://www.ncbi.nlm.nih.gov/books/NBK554178/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 3,
      "question": "Which of the following statements regarding the management of COPD is correct ?",
      "options": {
        "A": "Inhaled corticosteroids (ICS) should be used as monotherapy in all COPD patients",
        "B": "Long-acting bronchodilators are the mainstay of treatment for moderate to severe COPD",
        "C": "Antibiotics are routinely prescribed for the prevention of COPD exacerbations",
        "D": "Pulmonary rehabilitation is only recommended for patients with mild COPD"
      },
      "correct_answer": "B",
      "explanation": "severe COPD because they help improve lung function, reduce symptoms like breathlessness, and decrease the frequency of exacerbations. They form the cornerstone of maintenance therapy in these patients. Risk and Symptomatic Classification for Pharmacotherapy in Respiratory Medicine: General Principles: Identify and Address Underlying Cause Treating the underlying cause is key (e.g., treating heart failure resolves pleural effusion, treating pneumonia alleviates cough/breathlessness). Assess Severity GOLD Classification for COPD : Based on post-bronchodilator FEV1, guiding treatment escalation. mMRC Dyspnoea Scale : Assesses breathlessness severity, helps in decisions like pulmonary rehab or oxygen therapy. BODE Index for COPD : Uses BMI, airflow obstruction, dyspnoea, and exercise capacity to predict mortality risk and prioritise interventions. Individualise Treatment Comorbidities : Conditions like heart disease, diabetes, or renal impairment can affect drug choices. Drug Interactions : Consider interactions between respiratory and other medications. Patient Preferences : Shared decision-making regarding inhaler devices and treatment options. Inhaled corticosteroids (ICS) as monotherapy (Option A) is incorrect because ICS should not be used alone in COPD management. They are typically used in combination with bronchodilators in patients with frequent exacerbations. Antibiotics for prevention of exacerbations (Option C) is incorrect because antibiotics are reserved for acute exacerbations and not used routinely for prevention. Pulmonary rehabilitation only for mild COPD (Option D) is incorrect as pulmonary rehabilitation is recommended for patients with moderate to severe COPD, not just mild cases. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 564, 569, 570, 576, 583, 584, 620, 621, 622",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 4,
      "question": "A 62-year-old male with chronic obstructive pulmonary disease (COPD) reports increasing breathlessness over the past few months. He now has to stop for breath after walking about 100 metres on level ground. According to the modified Medical Research Council (mMRC) dyspnoea scale, which grade best describes his level of breathlessness?",
      "options": {
        "A": "Grade 1",
        "B": "Grade 2",
        "C": "Grade 3",
        "D": "Grade 4"
      },
      "correct_answer": "C",
      "explanation": "corresponds to mMRC Grade 3. mMRC Dyspnoea Scale: Purpose Assesses severity of breathlessness in respiratory diseases (e.g., COPD). Provides a numerical score for quantifying breathlessness. Helps monitor disease progression and guide treatment decisions. mMRC Scale Grades: Grade Description of Breathlessness 0 Not troubled by breathlessness except on strenuous exertion. 1 Short of breath when hurrying on the level or walking up a slight hill. (Option A ruled out) 2 Walks slower than others of the same age or stops for breath when walking. (Option B ruled out) 3 Stops for breath after walking 100 metres or after a few minutes on the level. 4 Too breathless to leave the house or breathless while dressing/undressing. (Option D ruled out) Uses of mMRC Scale: Quantifies severity of breathlessness in a standardised way. Monitors changes in breathlessness over time, indicating disease progression. Guides treatment, helping determine need for interventions like pulmonary rehabilitation or long-term oxygen therapy. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 575",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 5,
      "question": "Which of the following interventions has been shown to significantly improve survival in patients with chronic obstructive pulmonary disease (COPD)?",
      "options": {
        "A": "Pulmonary rehabilitation",
        "B": "Smoking cessation",
        "C": "Oral glucocorticoids during exacerbations",
        "D": "Pneumococcal vaccination"
      },
      "correct_answer": "B",
      "explanation": "slows the decline in lung function (FEV1) and alters the natural progression of the disease, significantly reducing mortality. Interventions for Improved Survival in COPD: Smoking Cessation: Most crucial intervention for improving survival. Slows decline in lung function (FEV1), altering disease progression. Long-Term Oxygen Therapy (LTOT): Improves survival in severe hypoxaemia (PaO2 < 7.3 kPa). Recommended use: at least 15 hours/day, with greater benefit at >20 hours/day. Pulmonary Rehabilitation: (Option A ruled out) Improves symptoms, exercise tolerance, and health status. May contribute to better survival, though direct link needs more research. Management of Exacerbations: Crucial for reducing mortality. Key components: Controlled oxygen therapy (24%-28%) to maintain PaO2 > 8 kPa. Nebulised bronchodilators: salbutamol + ipratropium. Oral glucocorticoids: prednisolone 30 mg for 10 days. (Option C ruled out) Antibiotics for increased sputum purulence/volume, breathlessness. Non-invasive ventilation (NIV) for mild-moderate acidosis (pH < 7.35). Vaccination: Annual influenza and pneumococcal vaccinations to prevent infections and exacerbations. (Option D ruled out) Multidisciplinary Management: Address comorbidities (e.g., obesity, malnutrition, depression, social isolation). These factors impact overall health and survival. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 576, 577, 578",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 6,
      "question": "A 65-year-old male with a history of chronic obstructive pulmonary disease (COPD) presents for routine follow-up. He reports increased breathlessness while walking on level ground and has experienced two exacerbations in the past year. According to the 2023 GOLD classification, which group does this patient belong to?",
      "options": {
        "A": "Group A: Low risk, low symptoms",
        "B": "Group B: Low risk, high symptoms",
        "C": "Group C: High risk, low symptoms",
        "D": "Group D: High risk, high symptoms"
      },
      "correct_answer": "D",
      "explanation": "breathlessness while walking on level ground, indicating significant symptoms, and his history of two exacerbations in the past year categorises him as high risk. 2023 GOLD Classification for COPD: 1. New Definition of COPD: Defined as a heterogeneous lung condition with chronic symptoms (dyspnea, cough, sputum production) and persistent airflow obstruction. Diagnosis: Based on FEV1/FVC ratio of <0.7 or LLN (Lower Limit of Normal). 2. Grouping System (A to E): Symptom Severity: Assessed using mMRC dyspnea scale or COPD Assessment Test (CAT). Risk of Exacerbations: Based on the patient's history over the past year. 3. Group Categories: 4. Exacerbation Definition Update: Exacerbation: A period of worsened dyspnea, cough, and sputum production (up to 14 days), often linked to infections or environmental factors. Management Strategies by Group: Group Treatment Goals A Short-acting bronchodilators (e.g., albuterol) as needed. Symptom control and improved quality of life. B Initiate long-acting bronchodilators (LABA/LAMA). Focus on symptom relief with low exacerbation risk. E (formerly C & D) LABA/LAMA or LABA + ICS (depending on exacerbation history). Comprehensive management to reduce symptoms and exacerbations. 5. Follow-Up and Reassessment: Regular assessment of dyspnea severity and exacerbation frequency. Adjust treatment based on evolving symptoms, exacerbation history, and comorbid conditions. 6. Special Considerations: Manage comorbidities without altering their treatment for COPD. Use inhaled corticosteroids (ICS) only for high-risk patients with frequent exacerbations to minimise unnecessary medication exposure.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 7,
      "question": "A 68-year-old woman with a history of Chronic Obstructive Pulmonary Disease (COPD) is evaluated for her BODE Index score. Her current Body Mass Index (BMI) is 20 kg/m², her post-bronchodilator FEV1 is 42% of the predicted value, she reports a mMRC dyspnoea score of 3, and she walks 340 metres during a 6-minute walk test. What is her total BODE Index score?",
      "options": {
        "A": "4",
        "B": "5",
        "C": "6",
        "D": "7"
      },
      "correct_answer": "C",
      "explanation": "(BMI) : 1 point (BMI < 21 scores 1). Obstruction (FEV1) : 2 points (FEV1 35-49% scores 2). Dyspnea (mMRC scale) : 2 points (mMRC score of 3 scores 2). Exercise Capacity : 1 point (walking 250-349 metres scores 1). Therefore, the total Therefore, her BODE score is 1 (BMI) + 2 (Obstruction) + 2 (Dyspnoea) + 1 (Exercise Capacity) = 6. BODE Index in COPD Overview: BODE Index : A multidimensional scoring system predicting mortality in COPD patients. Purpose : Offers a comprehensive assessment beyond just FEV1%. Components of the BODE Index: Component Description Score Range Body Mass Index (BMI) Measures body fat based on height and weight; lower BMI indicates poorer prognosis. 0 to 3 Obstruction Evaluated by post-bronchodilator FEV1% predicted; lower values signify severe airflow obstruction. 0 to 3 Dyspnoea Assessed using the modified MRC dyspnoea scale; higher scores indicate greater breathlessness. 0 to 3 Exercise Capacity Measured by the distance walked in 6 minutes; shorter distances reflect poorer exercise tolerance. 0 to 3 Calculation and Interpretation Total BODE Score : Sum of individual component scores, ranging from 0 to 10. Prognosis : Score 0-2: ~10% mortality rate over 52 months. Score 7-10: ~80% mortality rate over the same period. Importance of the BODE Index Comprehensive Assessment : Evaluates overall health status and disease severity in COPD patients. Guides Treatment Decisions : Aids in tailoring interventions based on individual patient profiles. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 577",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Pulmonology-Bronchial_Asthma_And_Copd_Q7_exp.jpg",
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 8,
      "question": "A 70-year-old male with a long-standing history of chronic obstructive pulmonary disease (COPD) presents to the clinic with worsening breathlessness and cough. His smoking history is significant for 45 pack-years. O/E, he has bilateral wheezes and a respiratory rate of 24 breaths per minute. His oxygen saturation is 89% on room air, and spirometry confirms a post-bronchodilator FEV1/FVC ratio of 60%. Which of the following is the most appropriate first-line treatment to improve his breathlessness and reduce the risk of exacerbations?",
      "options": {
        "A": "Oral theophylline combined with ICS",
        "B": "Long-acting bronchodilator (LABA) combined with an inhaled glucocorticoid",
        "C": "Long-term oxygen therapy",
        "D": "Pulmonary rehabilitation"
      },
      "correct_answer": "B",
      "explanation": "improving lung function, reducing breathlessness, and decreasing the frequency and severity of exacerbations in moderate to severe COPD patients. Combination therapy is more effective than bronchodilators alone. Management of COPD: 1. Reducing Exposure to Noxious Particles and Gases Smoking cessation is crucial and significantly slows down the decline in lung function (FEV1). Alternatives to smoking should be encouraged (e.g., non-smoking cooking devices). Occupational exposures (e.g., coal dust, silica) should be minimised. 2. Pharmacological Management: Medication Key Points Bronchodilators Central to managing COPD ; inhaled route preferred. Short-acting for mild cases; long-acting for moderate to severe cases. Oral bronchodilators (e.g., theophylline) are a second option due to side effects. (Option A ruled out) Inhaled Glucocorticoids Combined with LABAs to improve lung function, reduce exacerbations, and improve quality of life. Risk of pneumonia in elderly patients. Triple therapy adds a LAMA to LABA/glucocorticoid combo. (Option B) Oral Glucocorticoids Used in acute exacerbations but avoided long-term due to side effects (e.g., osteoporosis). 3. Non-Pharmacological Management: Management Details Pulmonary Rehabilitation Involves exercise, education, and nutrition counselling. Reduces symptoms, improves exercise tolerance and quality of life. Typically lasts 6–12 weeks. (Option D ruled out) Oxygen Therapy Long-term oxygen therapy (LTOT) for patients with severe hypoxaemia (PaO2 < 7.3 kPa). Use >15 hours/day improves survival. Ambulatory oxygen for patients desaturating on exercise. (Option C ruled out) Surgical Intervention Bullectomy and lung volume reduction surgery (LVRS) for upper lobe emphysema or large bullae. Lung transplantation for advanced cases. 4. Other Measures: Annual influenza and pneumococcal vaccinations recommended. Manage comorbidities (e.g., obesity, depression) to improve health outcomes. Limited evidence for mucolytic agents. 5. Palliative Care: Focuses on quality of life and symptom control in advanced COPD. Morphine for breathlessness, benzodiazepines for anxiety. Discuss resuscitation preferences with patients before critical illness. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 576, 577",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 9,
      "question": "A 62-year-old woman with a history of chronic obstructive pulmonary disease (COPD) presents with increased breathlessness, cough, and sputum production over the last two days. She appears distressed and has a respiratory rate of 28 breaths per minute. Her oxygen saturation is 88% on room air. Which of the following management strategies is most appropriate for her immediate treatment?",
      "options": {
        "A": "Initiate high-flow oxygen therapy to maintain oxygen saturation above 95%",
        "B": "Start nebulised bronchodilator therapy with salbutamol and ipratropium",
        "C": "Begin intravenous glucocorticoids immediately",
        "D": "Order a chest X-ray before any treatment is provided"
      },
      "correct_answer": "B",
      "explanation": "treatment for this patient experiencing an acute exacerbation of COPD. This therapy helps relieve bronchospasm and improve airflow, which is critical given her increased breathlessness and distress. Treatment of Acute Exacerbation of COPD: Initial Management and Assessment: Symptoms: Increased breathlessness, cough, sputum production; deterioration in lung function and health status. Triggers: Usually bacterial or viral infections, or changes in air quality. Home management: Increased bronchodilator therapy, short course of oral glucocorticoids, and possibly antibiotics. Hospital referral indicators: Cyanosis Peripheral oedema Altered consciousness Comprehensive assessment upon admission: Level of consciousness (response to commands, ability to cough) Signs of CO2 retention (warm peripheries, bounding pulse, flapping tremor) Airway obstruction assessment (wheeze, prolonged expiration) Signs of cor pulmonale (peripheral oedema, raised JVP) Background functional status and quality of life Precipitating causes (e.g., infection, environmental factors) Investigations: Investigation Purpose/Findings Arterial blood gases Assess severity of hypoxaemia, hypercapnia, acidaemia; guide oxygen therapy and ventilation. Chest X-ray Identify complications such as pneumonia, pneumothorax, or pleural effusion. (Option D ruled out) Management Strategies: Management Details Oxygen Therapy Administer controlled oxygen at 24% or 28% to maintain PaO2 > 8 kPa (60 mmHg) or SaO2 > 90%. (Option A ruled out) Regular arterial blood gas monitoring to adjust therapy. Bronchodilators Use nebulised short-acting β 2-agonists (e.g., salbutamol, terbutaline) with anticholinergics (e.g., ipratropium). If oxygen sensitivity is a concern, use compressed air for nebulisation. Glucocorticoids Administer oral prednisolone (30 mg for 10 days) to reduce symptoms and improve lung function.Reduces frequency and severity of exacerbations. Consider osteoporosis prophylaxis for repeated courses. Antibiotic Therapy Indicated for increased sputum purulence, volume, or breathlessness. Use simple regimens (aminopenicillin, tetracycline, macrolide); co-amoxiclav in areas with β -lactamase organisms. Non-Invasive Ventilation (NIV) Safe for mild to moderate respiratory acidosis; helps reduce intubation need and mortality. Not suitable for patients unable to protect their airway. Mechanical Ventilation Consider if there is a reversible cause, no prior respiratory failure, or if NIV has failed/contraindicated. Decisions should involve the patient, family, and GP. Additional Therapy Diuretics for peripheral oedema. Limited evidence for intravenous aminophylline; consider arrhythmia risk. Doxapram may be used short-term for low respiratory rates. Discharge and Follow-Up: Discharge criteria: Clinically stable on maintenance medication. Off nebulised therapy for at least 24 hours. PEF reaches 75% of predicted or personal best. Post-exacerbation follow-up: Identify and avoid trigger factors. Provide asthma education and a written self-management plan. Begin",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 10,
      "question": "A 55-year-old man presents with a 6-month history of worsening breathlessness, chronic cough, and occasional sputum production. He has a 30-pack-year smoking history. On examination, there is no finger clubbing, and pulse oximetry shows oxygen saturation of 92% on room air. Spirometry reveals an FEV1/FVC ratio of 60% post-bronchodilator. What is the most appropriate next investigation to assess the severity of his condition?",
      "options": {
        "A": "Chest X-ray",
        "B": "Blood gas analysis",
        "C": "High-resolution computed tomography (HRCT)",
        "D": "Spirometry with post-bronchodilator FEV1%"
      },
      "correct_answer": "D",
      "explanation": "FEV1% predicted value helps to classify the severity and guide management. History and Examination for Suspected COPD: COPD suspicion: In patients over 40 with chronic bronchitis symptoms or breathlessness. Detailed history: Smoking, occupational exposures, environmental pollutants. Symptom inquiry: Cough, sputum production, breathlessness, oedema, morning headaches. Haemoptysis: Requires thorough investigation to exclude other causes. Physical signs: Often poorly correlated with lung function until advanced disease. Finger clubbing: Not a feature of COPD ; may indicate lung cancer or fibrosis. Investigations: Investigation Purpose/Findings Chest X-ray Detects alternative diagnoses, complications like cor pulmonale, bullae, cardiac failure, or lung cancer. (Option A ruled out) Blood count Excludes anaemia, detects polycythaemia or infection. Assays α 1-antitrypsin in younger patients. Spirometry Confirms airflow obstruction (post-bronchodilator FEV1/FVC < 70%), assesses COPD severity. (Option D) Lung volume measurement Assesses hyperinflation, uses helium dilution or body plethysmography for severe cases. Gas transfer measurement Low gas transfer suggests emphysema. Exercise tests Assesses exercise tolerance, response to therapy, and prognosis. Pulse oximetry Identifies need for domiciliary oxygen (O2 saturation < 93%). High-resolution CT (HRCT) Detects, characterises, quantifies emphysema, guides lung volume reduction surgery. Arterial blood gas analysis Assesses respiratory failure and acid-base status. (Option A ruled out) Assessing Severity and Impact: Severity: Traditionally defined by post-bronchodilator FEV1% predicted. (Option D) Clinical impact assessment: Based on symptoms, activity limitation, and exacerbation frequency/severity. GOLD Staging : Stage FEV I % of Predicted Symptoms Exacerbations (Risk) I (Mild) FEV I ≥ 80% of predicted Often none or mild symptoms Rare or no exacerbations II (Moderate) FEV I 50–79% of predicted Symptoms worsen with exertion 1 or more exacerbations per year III (Severe) FEV I 30–49% of predicted Severe symptoms, limits daily activities Frequent exacerbations IV (Very Severe) FEV I < 30% of predicted or FEV I < 50% with chronic respiratory failure Very severe symptoms, respiratory failure may occur Very frequent exacerbations, potentially life-threatening High-resolution computed tomography (HRCT) (Option C): More sensitive than a chest X-ray for detecting emphysema, but it is not routinely used for severity assessment unless surgical intervention is being considered. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 575, 576",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 11,
      "question": "A 65-year-old man with a 40-pack-year smoking history presents with chronic productive cough, worsening breathlessness, and peripheral oedema. Physical examination reveals central cyanosis and ankle swelling. Arterial blood gas analysis shows raised PaCo2and hypoxia. Which of the following conditions best describes the patient's clinical phenotype?",
      "options": {
        "A": "Pink puffer",
        "B": "Blue bloater",
        "C": "Bronchiectasis",
        "D": "Asthma"
      },
      "correct_answer": "B",
      "explanation": "cough, peripheral oedema,central cyanosis, hypercapnia, and hypoxia. This best fits the patient's clinical presentation. Features of COPD ('Blue Bloaters'): Blue bloaters: Characterised by early development or tolerance of hypercapnia, oedema, and secondary polycythaemia. Feature Description Hypercapnia Elevated CO2 levels in the blood. Polycythaemia Increased red blood cell concentration due to chronic low oxygen. Oedema Fluid retention, often linked to renal hypoxia and hypercapnia. Common symptoms Cough, sputum production, breathlessness, oedema, morning headaches. Note: The \"pink puffers\" and \"blue bloaters\" phenotypes often overlap in practice. Other Potential Features of COPD: Chronic bronchitis: Persistent cough with sputum for at least 3 months over 2 consecutive years. Emphysema: Permanent enlargement of airspaces beyond terminal bronchioles with airway wall destruction (no fibrosis). Airflow limitation: Leads to gas trapping, hyperinflation, and increased work of breathing. Weight loss & skeletal muscle dysfunction: Extrapulmonary effects. Common co-morbidities: Cardiovascular disease, cerebrovascular disease, metabolic syndrome, osteoporosis, depression, lung cancer. Additional Notes: Physical signs: Poor correlation with lung function; often not noticeable until advanced disease. Haemoptysis: Requires thorough investigation to exclude other causes before attributing to COPD. Pink puffer (Option A): Typically refers to the emphysema-dominant COPD phenotype, characterised by dyspnoea, a thin body habitus, and hyperinflation, but not peripheral oedema or early hypercapnia. Bronchiectasis (Option C): While bronchiectasis can present with a chronic productive cough, it is associated with recurrent respiratory infections rather than the chronic hypoxia and hypercapnia seen in blue bloaters. Asthma (Option D): Asthma usually presents with reversible airway obstruction and episodic symptoms like wheezing, rather than chronic hypercapnia and peripheral oedema. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 574, 575",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 12,
      "question": "A 65-year-old male patient presents with a history of chronic cough and sputum production for the past several years. He is thin and exhibits significant breathlessness primarily during physical activity, but he reports minimal symptoms at rest. Arterial blood gas analysis shows a normal PaCO2. Which of the following is the most likely diagnosis for this patient?",
      "options": {
        "A": "Chronic bronchitis",
        "B": "Asthma",
        "C": "Emphysema",
        "D": "Interstitial lung disease"
      },
      "correct_answer": "C",
      "explanation": "normal PaCO2 until late stages, and chronic cough/sputum production. This aligns with the patient's presentation. Features of COPD (Pink Puffers) Definition: \"Pink puffers\" refer to a phenotype of COPD characterized by thin, breathless patients who typically maintain normal PaCO2 levels until late-stage disease. Feature Description Symptoms Cough and sputum production (often \"smoker's cough\") Breathlessness, mainly during physical activity with minimal symptoms at rest or overnight Physical Examination Quiet breath sounds Thin body habitus Possible crackles on lung auscultation, particularly with infection Late-stage may show finger clubbing (not typical for COPD, warrants further investigation) Arterial Blood Gasses Normal PaCO2 (35-45 mmHg) until late-stage Increased PaCO2 leads to respiratory acidosis as the disease progresses Chest X-Ray May show emphysema but often normal until advanced stages Pulmonary Function Tests Airflow obstruction Reduced FEV1/FVC ratio <70% (key indicator of COPD) Treatment Goals Improve breathlessness Reduce frequency and severity of exacerbations Enhance health status and prognosis Common Treatments Smoking cessation Inhaled bronchodilators Inhaled corticosteroids Oxygen therapy Pulmonary rehabilitation Prognosis Usually progressive with variable natural history Prognosis inversely related to age and directly related to post-bronchodilator FEV1 Poor prognostic indicators include weight loss and pulmonary hypertension Chronic bronchitis (Option A) : Typically associated with overweight individuals (blue bloaters) who may have elevated PaCO2 levels and significant edema, which does not match this patient's profile. Asthma (Option B) : While it can cause breathlessness and cough, the chronic nature of the symptoms and the normal PaCO2 are more indicative of COPD, specifically emphysema. Interstitial lung disease (Option D) : This condition typically presents with progressive dyspnea and a dry cough, rather than the chronic cough and sputum production seen in this patient. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 557, 558, 575, 576, 577.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 13,
      "question": "A 65-year-old patient with a history of chronic obstructive pulmonary disease (COPD) presents with worsening shortness of breath and edema. Right heart catheterization reveals a mean pulmonary artery pressure of 30 mmHg. Which of the following statements about pulmonary hypertension (PH) in this patient is most accurate?",
      "options": {
        "A": "Pulmonary hypertension in COPD is primarily caused by increased left atrial pressure.",
        "B": "The prognosis of COPD is directly proportional to age.",
        "C": "Right ventricular hypertrophy may be observed on an electrocardiogram (ECG).",
        "D": "Treatment options for pulmonary hypertension in COPD primarily include corticosteroids."
      },
      "correct_answer": "C",
      "explanation": "(ECG). the right ventricle often hypertrophies as it works harder to pump blood against elevated pulmonary artery pressures. This hypertrophy can be detected on an ECG, typically presenting as right axis deviation ,increased QRS voltage and tall, peaked P wave. Due to enlarged right atrium (P pulmonale). Pulmonary Hypertension (PH) in COPD Definition : Mean pulmonary artery pressure (PAP) ≥ 25 mmHg at rest, confirmed via right heart catheterization. Causes : Most common cause: Respiratory failure from intrinsic pulmonary disease. Can be primary or secondary to: Connective tissue disease (e.g., systemic sclerosis). Chronic thromboembolic disease. Pathophysiology : Normal pulmonary circulation: ~24/9 mmHg, can handle increased flow with minimal pressure rise (e.g., during exercise). In COPD, PH arises from: (Option A ruled out) Destruction of pulmonary vessels due to emphysema. Obstruction by thrombus. Interstitial inflammation. Cor Pulmonale (Right-Sided Heart Failure) in COPD (Option C) Mechanism : Right ventricle undergoes hypertrophy due to PH which will eventually lead to right heart failure if untreated. ECG findings: Right axis deviation and P pulmonale (tall, peaked P waves). Clinical Features : Raised jugular venous pressure (JVP). Peripheral edema (salt and water retention). Enlarged liver. Treatment Options COPD Treatments Pulmonary Hypertension Treatments Smoking cessation (Most important) Diuretic therapy for right-sided heart failure Inhaled bronchodilators Supplemental oxygen Inhaled corticosteroids (glucocorticoids) (Option D ruled out) Double lung transplantation Oxygen therapy Pulmonary thromboendarterectomy (for chronic proximal pulmonary thromboembolic disease) Pulmonary rehabilitation Atrial septostomy Prognosis General COPD Prognosis : Variable and typically progressive. Inversely related to age. (Option B ruled out) Directly related to post-bronchodilator FEV1. Poor Prognostic Indicators : Weight loss. Presence of pulmonary hypertension. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 621, 622.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 14,
      "question": "A 60-year-old male with a long history of smoking presents to the clinic with chronic cough and wheezing. He mentions that he had multiple respiratory infections during childhood and was born with low birth weight. Which of the following factors is most likely to have the greatest impact on the progression of his Chronic Obstructive Pulmonary Disease (COPD)?",
      "options": {
        "A": "Airway hyper-reactivity",
        "B": "Tobacco smoke",
        "C": "Recurrent infections",
        "D": "Impaired lung growth"
      },
      "correct_answer": "B",
      "explanation": "driver of disease progression. Causes and Risk Factors of COPD Chronic Obstructive Pulmonary Disease (COPD) is a progressive condition marked by persistent airflow limitation and a chronic inflammatory response in the lungs. Exacerbations and comorbidities can worsen disease severity. Major Causes and Risk Factors Category Details Tobacco Smoke Primary risk factor ; risk increases with amount and duration of smoking; responsible for 90% of COPD cases . (Option B) Indoor Air Pollution Significant risk from cooking with biomass fuels (wood, dung) in enclosed spaces, especially in developing countries. Occupational Exposures Linked to exposure to coal dust, silica, and cadmium; coal worker's pneumoconiosis (CWP) can resemble COPD. Low Birth Weight Associated with lower lung function in adulthood, raising COPD risk. Impaired Lung Growth Influenced by childhood infections or maternal smoking, leading to reduced lung function later in life. (Option D ruled out) Recurrent Infections Can accelerate the decline in FEV1 (lung function) and alter inflammatory responses, increasing lung damage risk. (Option C ruled out) Genetic Factors Alpha1-antitrypsin deficiency reduces protective lung protein levels; other genetic susceptibility factors may also contribute. Airway Hyper-reactivity Increased sensitivity to environmental triggers, which may facilitate COPD development. (Option A ruled out) HIV Infection Associated with emphysema, a subtype of COPD. Low Socioeconomic Status Correlates with higher COPD risk, potentially due to multiple factors. Cannabis Smoking Identified as a contributing factor. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 574. 575, 576.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 15,
      "question": "A 10-year-old boy presents with wheezing and shortness of breath, worsening at night. His symptoms are triggered by dust and pet dander. Spirometry shows an obstructive pattern that improves with a bronchodilator. What is the underlying mechanism?",
      "options": {
        "A": "IgG-mediated immune complexes.",
        "B": "IgE-mediated mast cell degranulation.",
        "C": "Bronchial irritation from pollutants.",
        "D": "Viral infection causing airway remodeling."
      },
      "correct_answer": "B",
      "explanation": "to IgE production and subsequent mast cell activation (Type 1 hypersensitivity reaction) 1. Allergen Exposure/Sensitisation to allergen Allergens induce a TH2 phenotype in CD4+ T helper cells of genetically susceptible individuals. 2. TH2 Cytokine Secretion TH2 cells secrete: IL-4: Mediates class switch to IgE. IL-5: Attracts eosinophils. IL-13: Mucous production in respiratory tract. IL-10: Stimulates TH2 cells and inhibits TH1. 3. Reexposure to Allergen leads to allergic reaction Leads to IgE-mediated activation of mast cells. i. Early-Phase Reaction: Binding of IgE + allergen on mast cells Release of preformed histamine granules from mast cells . Generation of leukotrienes C4, D4, and E4. Results in: Bronchoconstriction Inflammation Edema ii. Late-Phase Reaction: Inflammation, particularly from major basic protein derived from eosinophils. Causes cellular damage and perpetuates bronchoconstriction. IgG-mediated immune complexes (Option A): is associated with type III hypersensitivity reactions, often seen in conditions like autoimmune diseases, rather than the immediate response seen in asthma. Bronchial irritation from pollutants (Option C): While pollutants can exacerbate asthma symptoms, they do not account for the specific IgE-mediated mechanism triggered by allergens like dust and pet dander. Viral infection causing airway remodeling (Option D): Viral infections can trigger asthma exacerbations, but they are not the primary mechanism in this case, especially given the clear allergic triggers and the characteristic response to bronchodilators.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 16,
      "question": "A 65-year-old male presents with progressive dyspnea and a history of smoking for 25 years. Imaging studies reveal abnormal enlargement of air spaces distal to the terminal bronchioles. Which of the following types of emphysema is most likely seen in this patient?",
      "options": {
        "A": "Panacinar emphysema",
        "B": "Paraseptal emphysema",
        "C": "Centriacinar emphysema",
        "D": "Bullous emphysema"
      },
      "correct_answer": "C",
      "explanation": "part of the acinus , often associated with smoking and chronic bronchitis. Classification of Emphysema Definition : Emphysema is a chronic obstructive pulmonary disease (COPD) marked by abnormal enlargement of air spaces beyond the terminal bronchioles, with wall destruction but no significant fibrosis. Pathophysiology : Caused by the unopposed action of proteases and oxidants. Leads to alveolar wall elastic tissue destruction and enlarged air spaces. Types of Emphysema : Type Description Centriacinar Enlarged air spaces primarily in the central part of the acinus. (Option C) seen in chronic smokers, upper lobe of lungs are predominantly affected. Panacinar Uniform enlargement of air spaces throughout the acinus. (Option A ruled out) seen with congenital alpha 1 antitrypsin deficiency in younger age group.lower lobes of lung are commonly involved.associated with liver failure. Paraseptal Enlargement occurs near the pleura or septa. (Option B ruled out) increase risk of spontaneous pneumothorax. Complications : Formation of bullae (large air-filled spaces) may occur. Results in impaired gas exchange and potential respiratory failure. Bullous emphysema (Option D) : Refers to the formation of large air-filled spaces (bullae) but is not a distinct type based on acinar structure. It can occur in various forms of emphysema.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 17,
      "question": "A 58-year-old male, with a 30-year history of smoking, presents with a chronic productive cough for the last 2 years, worsening shortness of breath, and recent weight loss. Examination reveals bilateral wheezing and peripheral edema imaging shows alveolar wall destruction beyond terminal bronchiole. Which of the following pathophysiological mechanisms is primarily responsible for his condition?",
      "options": {
        "A": "Pulmonary vascular remodeling",
        "B": "Alpha-1 antitrypsin deficiency",
        "C": "Airflow limitation due to loss of elastic tissue",
        "D": "Hypersecretion of mucus from goblet cells"
      },
      "correct_answer": "C",
      "explanation": "airway recoil, premature airway closure, and gas trapping, which are hallmarks of emphysema. Pulmonary vascular remodeling occurs in pulmonary hypertension, alpha-1 antitrypsin deficiency causes early-onset emphysema in younger individuals, and mucus hypersecretion indicates chronic bronchitis but does not account for alveolar destruction or weight loss. Pathogenesis of COPD Risk Factors Cigarette Smoking : Primary risk, correlates with amount and duration. Environmental Factors : Indoor air pollution (e.g., biomass fuel use in confined spaces). Occupational exposures (e.g., coal dust, silica, cadmium). Developmental Factors : Low birth weight and impaired lung growth from infections or maternal smoking. Infections : Recurrent infections accelerate lung decline. Persistent adenovirus may alter inflammatory responses, leading to damage. Genetic Factors : Alpha-1 antitrypsin deficiency . (Option B ruled out) Airway hyper-reactivity . Components of COPD Pulmonary Components Description Mucus hypersecretion Enlargement of mucus glands and goblet cells → chronic bronchitis (cough + sputum for ≥ 3 months/year). (Option D ruled out) Emphysema Alveolar destruction by proteases and oxidants → permanent enlargement of distal airspaces. Airflow Limitation Loss of elastic tissue + inflammation → premature airway closure, gas trapping, and hyperinflation. This is the primary mechanism for the airflow limitation. (Option C) Pulmonary vascular remodeling Structural changes in pulmonary vessels.eventually causing PAH. (Option A ruled out) Systemic Components Description Weight Loss Altered fat metabolism. Skeletal Muscle Dysfunction Muscle impairment reduces physical capacity. Peripheral Edema Impaired kidney function → salt and water retention. Osteoporosis Decreased bone density. Increased Inflammatory Markers Elevated systemic inflammation contributes to complications. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 574. 575, 576",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 18,
      "question": "A 42-year-old woman presents to the emergency department with worsening asthma symptoms, fever, and a rash consisting of purpura on her lower extremities. Laboratory findings reveal eosinophilia (1200 cells/ µ L) and elevated inflammatory markers. A biopsy of the skin lesion shows extravascular granulomas. Which of the following statements about her condition is false? vessels.",
      "options": {
        "A": "Patients often present with systemic symptoms like malaise and weight loss.",
        "B": "The condition typically involves necrotizing vasculitis affecting small and medium-sized blood",
        "C": "Cardiac involvement may lead to complications such as myocarditis and pericarditis.",
        "D": "It primarily affects large blood vessels, leading to significant vascular occlusion."
      },
      "correct_answer": "D",
      "explanation": "asthma, peripheral and tissue eosinophilia, extravascular granuloma formation, and vasculitis of multiple organ systems Pathogenesis: Necrotizing vasculitis affects small- and medium-sized arteries, capillaries, veins, and venules (Option B ruled out) Extravascular granulomas are found in tissues and vessel walls Clinical Manifestations: Systemic symptoms: Fever, malaise, anorexia, weight loss (Option A ruled out) Can affect any organ, with lung involvement being predominant Pulmonary findings: Severe asthma attacks, and pulmonary infiltrates Neurological: Mononeuritis multiplex (second most common manifestation) Cardiac involvement: Myocarditis, pericarditis, endocarditis, coronary vasculitis (Option C ruled out) Skin: Purpura, cutaneous, and subcutaneous nodules Renal involvement: Glomerulonephritis Diagnosis: Eosinophilia: Levels >1000 cells/ µ L Inflammatory markers: Elevated ESR and/or CRP p-ANCA: Positive in some cases. Treatment: Glucocorticoids Other immunosuppressants: Cyclophosphamide, azathioprine, methotrexate Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 2809-10",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 19,
      "question": "A 45-year-old male presents with chronic shortness of breath, dry cough, fatigue, and weight loss for the past six months. He works in a pigeon breeding facility and reports worsening symptoms over time. High-resolution CT (HRCT) of the chest reveals reticular changes, ground-glass opacities, and traction bronchiectasis. Which of the following statements about his condition is true?",
      "options": {
        "A": "It is caused by a Type I hypersensitivity reaction mediated by IgE antibodies.",
        "B": "Pulmonary fibrosis is a known complication of chronic HP.",
        "C": "Acute HP presents with symptoms several days after antigen exposure.",
        "D": "HRCT is typically normal in hypersensitivity pneumonitis."
      },
      "correct_answer": "B",
      "explanation": "lung damage , which can result in fibrosis . The patient’s history of chronic symptoms with pigeon exposure supports the diagnosis of Bird Fancier’s Lung . HRCT findings such as traction bronchiectasis and reticular changes indicate fibrotic changes . Hypersensitivity Pneumonitis (HP) Also known as extrinsic allergic alveolitis It is a pulmonary disease that occurs due to inhalational exposure to a different kinds of antigens leading to an inflammatory response of the alveoli and small airways Etiopathogenesis: (Option A ruled out) An immune-mediated condition triggered by inhaled antigens (Type III hypersensitivity reaction) Antigens are small enough to deposit in distal airways and alveoli Sensitization leads to IgG antibody formation against specific antigens.(Type 3 hypersensitivity) and activated helper T cells. (Type IV hypersensitivity reaction) Disease Antigen Source Farmer’s lung Thermophilic actinomycetes (e.g., Saccharopolyspora rectivirgula); fungus Grain, mouldy hay, silage Bagassosis Thermophilic actinomycetes Sugarcane Bird fancier’s lung Proteins derived from parakeets, pigeons, budgerigars Bird feathers, droppings, serum proteins Hot tub lung Cladosporium species; Mycobacterium avium complex Contaminated water, mould on ceiling Woodworker’s lung Alternaria species; Bacillus subtilis Oak, cedar, pine, mahogany dusts Clinical Manifestations: Acute HP: Onset: 4–8 hours after intense antigen exposure. (Option C ruled out) Symptoms: Fever, chills, malaise, dyspnea. Subacute HP: Ongoing antigen exposure leads to gradual onset over weeks. Symptoms: Gradual development of respiratory and systemic symptoms. Chronic HP: Slow onset with progressive dyspnea, cough, fatigue, weight loss, and clubbing. Can lead to lung fibrosis. (Option B) Diagnosis: Chest X-ray: Nonspecific findings; micronodular opacities or ground-glass opacities High-Resolution CT (HRCT): (Option D ruled out) Air trapping due to the involvement of the small airways Chronic HP: reticular changes, traction bronchiectasis Subpleural honeycombing in advanced cases Pulmonary Function Testing: Restrictive or obstructive patterns Serological Testing: IgG antibodies against specific antigens Bronchoscopy with Bronchoalveolar Lavage (BAL): Shows lymphocytosis Lung Biopsy: Non-necrotizing granulomas, peribronchial inflammatory infiltrate, chronic fibrosis Treatment: Avoidance of antigens is very important Glucocorticoid therapy: For subacute and chronic cases Lung transplantation: In advanced chronic HP with extensive lung fibrosis Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 2160-62.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 20,
      "question": "Which of the following statements best characterizes brittle asthma?",
      "options": {
        "A": "Symptoms develop gradually over a few days, allowing time for preventive action.",
        "B": "It is characterized by sudden exacerbations with little or no warning.",
        "C": "Patients with brittle asthma typically have heightened awareness of airway narrowing.",
        "D": "The primary cause of brittle asthma is well understood and easily managed."
      },
      "correct_answer": "B",
      "explanation": "early detection and preventive action difficult. Many patients also have a blunted perception of airway narrowing , leading to delayed diagnosis and severe outcomes. Brittle Asthma Definition : A severe form of asthma characterized by unpredictable attacks with little or no warning. Onset : Exacerbations occur suddenly with severe symptoms, unlike typical asthma, where symptoms develop gradually over hours or days. Challenges : Difficulty in recognizing early warning signs. Preventive measures are often delayed due to rapid deterioration. Types of BRITTLE ASTHMA: Brittle asthma is a severe form of asthma characterized by sudden and extreme fluctuations in symptoms, which can be life-threatening. It's typically classified into two main types based on the pattern of symptoms: 1. Type 1 (Mostly with sudden severe exacerbations) Characteristics : This type involves frequent, sudden, and extreme worsening of symptoms, which can occur without warning. These exacerbations are typically severe and can lead to respiratory failure or the need for hospitalization. It can happen even when the asthma is well-controlled in between exacerbations. There may be a history of frequent or severe asthma attacks despite regular treatment. 2. Type 2 (Frequent fluctuations in symptoms despite treatment) Characteristics : This type is marked by persistent severe symptoms that can fluctuate, despite the patient being on adequate asthma treatment. Even with regular use of medications like corticosteroids or bronchodilators, the patient's asthma control is unstable, with frequent flare-ups. Symptoms may not be as sudden as in Type 1, but the overall asthma management is challenging Key Factors Factor Description Patient Perception Some patients have a blunted awareness of airway narrowing, making it hard to detect early symptoms. Unpredictability Sudden onset and severity complicate management and timely intervention. Impact on Treatment Lack of awareness leads to delayed treatment , increasing the risk of severe exacerbations. Symptoms develop gradually over a few days, allowing time for preventive action. (Option A) : Unlike typical asthma, where symptoms develop gradually, brittle asthma progresses suddenly. Patients with brittle asthma typically have heightened awareness of airway narrowing . (Option C) : Many patients with brittle asthma have blunted perception of airway narrowing, contributing to delayed treatment. The primary cause of brittle asthma is well understood and easily managed. (Option D) : The underlying causes of brittle asthma are not well understood, and management remains challenging due to its unpredictability. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 570",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 21,
      "question": "A 35-year-old male with a history of asthma presents with symptoms occurring four times a week, occasional nighttime awakenings, and the need for rescue inhaler use three times a week. His post-bronchodilator FEV1 is 72% of the predicted value. According to the asthma classification guidelines, how would you categorize the severity and control of his asthma?",
      "options": {
        "A": "Mild asthma, controlled",
        "B": "Moderate asthma, partly controlled",
        "C": "Severe asthma, uncontrolled",
        "D": "Moderate asthma, uncontrolled"
      },
      "correct_answer": "B",
      "explanation": "symptoms > 2 times per week → partly controlled . Nocturnal symptoms present → partly controlled . Use of rescue inhaler > 2 times per week → partly controlled . Classification of Asthma Severity Spirometry Assessment : Post-bronchodilator FEV1 : Air exhaled in one second after bronchodilator use. FEV1/FVC Ratio : Indicates obstruction if <0.7. Severity Categories: Mild : FEV1 ≥ 80% of predicted (Option A ruled out) Moderate : FEV1 50-79% of predicted (Option B) Severe : FEV1 30-49% of predicted (Option C ruled out) Very Severe : FEV1 < 30% of predicted Classification Systems: ATS/ERS (2004) GOLD (2008) NICE Clinical Guideline 101 (2010) Clinical Assessment : Evaluates patient symptoms , activity limitations , and exacerbation frequency . Provides a comprehensive view of asthma's impact on the individual. Asthma Control Assessment Characteristic Feature Controlled (Option A ruled out) Partly Controlled (Option B) Uncontrolled (Options C & D ruled out) Daytime Symptoms None Symptoms > twice/week Frequent daytime symptoms Limitations of Activities None Any limitations Significant limitations Nocturnal Symptoms None Any nighttime symptoms Frequent nighttime symptoms Need for Rescue Treatment < twice/week > twice/week Frequent use of rescue medication Lung Function Normal (PEF or FEV1) < 80% of predicted/personal best Significantly reduced lung function Exacerbations None ≥ 1 per year Weekly exacerbations Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 570, 576",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 22,
      "question": "A 30-year-old patient with a history of asthma presents with symptoms occurring more than three times a week and nocturnal awakenings at least once a week. After evaluating the patient's condition, the physician decides to initiate treatment. Which of the following is the most appropriate initial step in the management of this patient? β 2-agonist. β 2-agonist (LABA).",
      "options": {
        "A": "Increase the dose of short-acting",
        "B": "Start regular inhaled glucocorticoids (ICS).",
        "C": "Start prednisolone at the lowest effective dose.",
        "D": "Add a long-acting"
      },
      "correct_answer": "B",
      "explanation": "a need for preventive therapy with ICS, which is the first-line treatment for patients experiencing frequent asthma symptoms. Asthma Treatment: Stepwise Approach Treatment Goals Achieve and maintain asthma control. Reduce frequency and severity of exacerbations. Improve overall health status. Minimize reliance on oral glucocorticoids. Treatment Steps Step Description Key Points Step 1 Occasional Short-Acting β 2-Agonists(rescue therapy) For mild, intermittent asthma (symptoms <1/week, <2 nocturnal episodes/month). Use bronchodilators like salbutamol or terbutaline as needed. Step 2 Regular Preventer Therapy Initiate if exacerbations occur within 2 years or symptoms are frequent ( ≥ 3/week) or nocturnal awakenings occur weekly. Inhaled Glucocorticoids (ICS) : e.g., beclometasone, budesonide (starting dose: 400 µ g/day for adults). Alternatives: Chromones, leukotriene receptor antagonists, theophyllines. Step 3 Add-on Therapy Review adherence, inhaler technique, and aggravating factors if poorly controlled. Increase ICS dose or add Long-Acting β 2-Agonist (LABA) ; combination inhalers are beneficial. (Options A & D ruled out) Consider oral leukotriene receptor antagonists (e.g., montelukast 10 mg/day) if needed. Step 4 Addition of a Fourth Drug For inadequate control with moderate ICS dose, increase to 2000 µ g/day or add nasal glucocorticoids for upper airway symptoms. Other options: Long-acting antimuscarinics, theophyllines, slow-release β 2-agonists. Discontinue ineffective add-on therapies. Step 5 Continuous/Frequent Oral Glucocorticoids Prescribe prednisolone at the lowest effective dose, typically in the morning. (Option C ruled out) Monitor for systemic side effects (long-term use risks). Consider Omalizumab for atopic patients or Mepolizumab for eosinophilic cases. Immunosuppressants are less common due to variable efficacy and side effects. Step-down Therapy Gradually reduce ICS or glucocorticoid doses to the lowest effective levels once control is achieved. Suggested reduction: 25–50% every three months. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 569, 570, 571, 572",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 23,
      "question": "A 24-year-old male presents with recurrent episodes of chest tightness, wheezing, and shortness of breath 10 minutes after running. The symptoms usually resolve within 30 minutes. Which of the following is the most appropriate pre-exercise treatment?",
      "options": {
        "A": "Long-acting beta agonist (LABA) taken daily",
        "B": "Short-acting beta agonist (SABA) used 15 minutes before exercise",
        "C": "Inhaled corticosteroid (ICS) used immediately after exercise",
        "D": "Leukotriene receptor antagonist (LTRA) taken during an acute episode"
      },
      "correct_answer": "B",
      "explanation": "exercise. They relax bronchial smooth muscle and increase the threshold for bronchoconstriction. Exercise-Induced Asthma (EIA) It is a transient and reversible bronchial smooth muscle contraction after physical exertion. Exercise can induce bronchoconstriction in both asthmatics and non-asthmatics. Pathogenesis: Hyperventilation that occurs with exercise dries the airway lining, changing the tonicity of lining cells and causing the release of bronchoconstrictive mediators. Cold air has a lower moisture content, aggravating bronchoconstriction. Cold air may also cause airway oedema during airway rewarming. Clinical Manifestations: Symptoms occur within 15 minutes after 5 to 8 minutes of high-intensity exercise. Mild to moderate symptoms: Chest tightness, wheezing, coughing, dyspnea. Reduced exercise tolerance or inability to exercise as desired. Diagnosis: Exercise Challenge Testing: A fall in FEV1 ≥ 10% is diagnostic of EIA. Fractional Excretion of Nitric Oxide (FENO) Testing: Measures Th2 inflammatory response due to airway hyperresponsiveness. Treatment: Exercise modification: Start at a lower intensity and gradually increase (warming up). Use a mask in cold weather to condition inhaled air. Medications: SABA (Short-Acting Beta Agonist): Pre-exercise use increases the threshold for bronchoconstriction (Option B) LABA (Long-Acting Beta Agonist): May extend the period of protection, but their use alone in asthma is to be discouraged (Option A ruled out) ICS/LABA (Inhaled Corticosteroid/LABA): Can be used occasionally for exercise but not recommended for regular use due to ICS overexposure. (Option A ruled out) LTRAs (Leukotriene Receptor Antagonists): regularly used for exercise induced asthma to reduce frequency of symptoms but for pre exercise treatment, these are not effective. (Option D ruled out) Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 2153, 2158, 2159 Exercise-Induced Bronchoconstriction - StatPearls - NCBI Bookshelf",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 24,
      "question": "A 28-year-old woman presents with a history of recurrent wheezing and shortness of breath, particularly during the winter months. She reports that her symptoms worsen with cold air and after respiratory infections. She does not have any known allergies, and her skin prick tests for common allergens are negative. What is the most likely diagnosis?",
      "options": {
        "A": "Atopic asthma",
        "B": "Occupational asthma",
        "C": "Intrinsic asthma",
        "D": "Cough-variant asthma"
      },
      "correct_answer": "C",
      "explanation": "sensitization (negative skin tests) and triggers primarily related to respiratory infections and environmental factors. Intrinsic asthma (non-atopic asthma): Aspect Details Sensitization No evidence of allergen sensitization Skin test results usually negative Family history Less common positive family history of asthma Common triggers Respiratory infections (e.g., rhinovirus, parainfluenza virus, respiratory syncytial virus) Inhaled air pollutants (tobacco smoke, sulfur dioxide, ozone, nitrogen dioxide) Other triggers Cold exposure Exercise Chronic inflammation Contributes to chronic airway inflammation and hyperreactivity Overlap with atopic asthma Some triggers (e.g., viral infections, air pollutants) can also trigger atopic asthma Atopic asthma (Option A): This type typically presents with positive allergen sensitization, which is not the case here. Occupational asthma (Option B): There is no indication of specific workplace-related triggers mentioned in the vignette. Cough-variant asthma (Option D): While this condition is characterized by severe coughing, the predominant symptoms of wheezing and shortness of breath align more with intrinsic asthma. Reference: Robbins and Cotran Pathologic Basis of Disease, South Asian Edition, 10th Edition, Page 683",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 25,
      "question": "A 10-year-old girl presents with recurrent wheezing and difficulty breathing, especially during spring. Her symptoms worsen at night and with exercise. She has a family history of asthma. Physical examination reveals wheezing and a skin prick test shows positive reactions to grass pollen. What is the most likely diagnosis?",
      "options": {
        "A": "Exercise-induced asthma",
        "B": "Extrinsic asthma",
        "C": "Intrinsic Asthma",
        "D": "Non-atopic asthma"
      },
      "correct_answer": "B",
      "explanation": "her positive skin prick test indicate that she has extrinsic asthma (also known as allergic asthma). Extrinsic asthma (atopic asthma): Aspect Details Type of Hypersensitivity IgE-mediated (Type I) Onset Usually begins in childhood Common Triggers Environmental allergens (dust, pollen, cockroach dander, animal dander, certain foods) Cofactors Respiratory viral infections Family History Positive family history of asthma Diagnosis Immediate wheal-and-flare reaction in skin tests High total serum IgE levels RAST for specific IgE antibodies Immunologic Reaction Th2 and IgE-mediated Acute-phase (immediate) and late-phase reactions Key cytokines: IL-4, IL-5, IL-13 Key inflammatory cells: Eosinophils, mast cells, neutrophils, T lymphocytes Exercise-induced asthma (Option A): While her symptoms worsen with exercise, this option does not encompass the allergic component indicated by the skin prick test.Drug of choice in excercise induced asthma:Leukotriene antagonist-montelukast , zafirlukast Intrinsic asthma /Non atopic asthma(Options C & D): This form of asthma is not related to allergies and typically occurs in adults, making it less likely in this pediatric case. Reference: Robbins and Cotran Pathologic Basis of Disease, 10th Edition, Page 683",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 26,
      "question": "A 40-year-old man presents to the clinic with a history of asthma. He reports that he has been using his rescue inhaler (SABA) more frequently, experiencing symptoms on most days and waking up at least twice a week due to shortness of breath. His current management includes as-needed SABA but no regular controller medication. What is the most appropriate next step in his asthma management?",
      "options": {
        "A": "Continue current treatment and monitor symptoms.",
        "B": "Start low-dose inhaled corticosteroids for daily control.",
        "C": "Increase the dosage of the SABA.",
        "D": "Add a leukotriene receptor antagonist for better control."
      },
      "correct_answer": "B",
      "explanation": "this indicates inadequate asthma control. According to asthma management guidelines, the next appropriate step is to initiate low-dose inhaled corticosteroids to provide consistent control of inflammation and reduce the frequency of symptoms. Reliever / Rescue therapy of choice: Low dose ICS - Formeterol inhaler . Maintenance / Controller therapy of choice: Reference: ginasthma.org/gina-reports/",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Pulmonology-Bronchial_Asthma_And_Copd_Q26_exp.png",
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 27,
      "question": "A 35-year-old man presents with complaints of wheezing and shortness of breath that have worsened over the past few weeks. He notes that his symptoms often occur at night and are triggered by exposure to dust and exercise. Spirometry shows a FEV1/FVC ratio of 65%. After using a short-acting β 2-agonist, his FEV1 increases by 20%. Which of the following findings would most likely be observed in this patient?",
      "options": {
        "A": "Increased total lung capacity",
        "B": "Decreased DLCO",
        "C": "Increased forced vital capacity",
        "D": "Decreased residual volume"
      },
      "correct_answer": "A",
      "explanation": "after SABA administration . In asthma, patients often exhibit increased total lung capacity due to air trapping and hyperinflation caused by obstructed airflow. Test Details Spirometry/PFTs Best initial test IOC Obstructive pattern Reversible with short-acting β 2-agonists (SABAs) Findings: FEV1/FVC < 70% ↓ FEV1 Normal or ↓ FVC (Option C) ↑ Residual Volume (RV) (Option D) ↑ Total Lung Capacity (TLC) Normal or ↑ Diffusing Capacity of Lung for Carbon Monoxide (DLCO) (Option B) Reversibility: Increase in FEV1 ≥ 12% and >200 mL with SABA (albuterol) PFTs between exacerbations: Often normal Methacholine Challenge Tests for bronchial hyperresponsiveness Positive if ≥ 20% decrease in FEV1 Sensitive but not specific Arterial blood gas Early Respiratory alkalosis ( ↓ PaCO2, ↑ pH) due to hyperventilation Late Respiratory acidosis due to muscle fatigue (normalizing PaCO2, normalizing pH, ↓ PaO2) Chest X-ray Normal appearance to hyperinflation with flattening of the diaphragm Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 2154",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    },
    {
      "q_no": 28,
      "question": "Which of the following statements about the Hygiene hypothesis is incorrect?",
      "options": {
        "A": "Clean environments may impair immune system maturation in children.",
        "B": "Endotoxin exposure is essential for proper immune development.",
        "C": "Fetal immune system is suppressed to prevent rejection of maternal tissue.",
        "D": "Lack of exposure to germs is linked to a decreased risk of developing asthma."
      },
      "correct_answer": "D",
      "explanation": "asthma, not decreases it. Hygiene Hypothesis Proposes that extremely clean household environments in developed countries derail immune responses in young children. (Option A) Lack of exposure to germs may inadequately educate the immune system, leading to increased asthma development. Immune System Education Fetal immune system is suppressed to avoid rejecting maternal tissue. (Option C) Post-birth, the child’s immune system must learn to fend for itself. Epidemiological Support Allergic diseases and asthma are more common in environments with low levels of endotoxin (LPS). (Option B) LPS stimulates the immune system through TLR4 (Toll-like receptor 4), essential for immune education. Reference: pmc.ncbi.nlm.nih.gov/articles/PMC8012489/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Pulmonology-Bronchial Asthma And Copd"
    }
  ]
}
